Craft

Biophytis

Stock Price

€0.3

2024-10-29

Market Capitalization

€1.7 M

2024-10-29

Biophytis Summary

Company Summary

Overview
Biophytis (formerly known as Institut Biophytis) is a biotechnology company focused on the development of drug candidates for the treatment of age-related diseases. It develops therapeutics to restore the muscular and visual functions in diseases such as Sarcopenia and Duchenne muscular dystrophy (DMD). Its therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.
Type
Public
Status
Active
Founded
2006
HQ
Paris, FR | view all locations
Website
https://www.biophytis.com/en/
Cybersecurity rating
Sectors

Key People

  • Stanislas Veillet

    Stanislas Veillet, Chairman and Chief Executive Officer, Director

  • Jean Mariani

    Jean Mariani, Director

    • Pierre J Dilda

      Pierre J Dilda, Chief Scientific Officer

    • Waly Dioh

      Waly Dioh, Chief Operating Officer

      Operating MetricsView all

      Patent Families

      15

      Feb, 2021

      Patents (Europe)

      9

      Feb, 2021

      Patents (US)

      5

      Feb, 2021

      LocationsView all

      3 locations detected

      • Paris, IDF HQ

        France

        10 Rue Chateaubriand

      • Cambridge, MA

        United States

        210 Broadway #201

      • Paris, IDF

        France

        14 Av. de l'Opéra

      Biophytis Financials

      Summary Financials

      Net income (H1, 2025)
      (€3.5M)
      Cash (H1, 2025)
      €1.2M
      EBIT (H1, 2025)
      (€4.1M)
      Enterprise value
      $8.2M

      Footer menu